Cardiac biomarkers in the intensive care unit

Annals of Intensive Care

Volumn 2, Issue 1, 2012, Pages 1-11

  McLean, Anthony S ^a   Huang, Stephen J ^a  

^a NEPEAN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADRENOMEDULLIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; CREATINE KINASE MB; FATTY ACID BINDING PROTEIN; GAMMA INTERFERON; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 33; INTERLEUKIN 6; ISCHEMIA MODIFIED ALBUMIN; MICRORNA; PREGNANCY ASSOCIATED PROTEIN; REACTIVE OXYGEN METABOLITE; TROPONIN I; TROPONIN T;

ACUTE LUNG INJURY; ARTIFICIAL VENTILATION; BREATHING; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EMERGENCY WARD; HEART DISEASE; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART STRESS; HUMAN; INFLAMMATION; INTENSIVE CARE; INTENSIVE CARE UNIT; KIDNEY FAILURE; LUNG EMBOLISM; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEPSIS; THORAX PAIN; WOUND HEALING;

EID: 84859877200     PISSN: None     EISSN: 21105820     Source Type: Journal    
DOI: 10.1186/2110-5820-2-8     Document Type: Review

References (97)

1. Blankesteijn W, Cremmers E, Lutgens E, Cleutjens J, Daemen M, Smits J: Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice. Acta Physiol Scand 2001, 173:75-82.
2. Liao Y-H, Cheng X: Autoimmunity in myocardial infarction. Int J Cardiol 2006, 112:21-26.
3. Caforio A: Ciculating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Failure 2002, 4(4):411-417.
4. Cooper L: The heat is off: immunosuprression for myocarditis revisited. Eur Heart J 2009, 30:1936-1939.
5. Packard R, Libby P: Inflammation in atherosclerosis: from vascular biology to biomarker discover and risk prediction. Clin Chem 2008, 54:24-38.
6. Wittstein I, Thiemann D, Lima J, Baughman K, Schulman S, Gerstenblith G, Wu K, Rade J, Bivalacqua T, Champion: Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005, 352:539-548.
7. Dolci A, Panteghini M: The exciting story of cardiac biomarkers: from retrospective detection to gold diagnostic standard for acute myocardial infarction and more. Clin Chimica Acta 2006, 369:179-187.
8. Thygesen K, Alpert J, White H: Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007, 28:2525-2538.
9. Ooi D, Isotalo P, Veinot J: Correlation of antemortem serum creatine kinase, creatine kinase-MB, troponin I and troponin T with cardiac pathology. Clin Chem 2000, 46:338-344.
10. Parmacek M, Solaro R: Biology of troponin complex in cardiac myocytes. Prog Cardiovasc Dis 2004, 47:159-176.
11. Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, Lindahl B, Giannitsis E, Hasin Y, Galvani M, Tubaro M, Alpert J, Biasucci L, Koenig W, Mueller C, Huber K, Hamm C, Jaffe A: Recommendations for the use of cardiac troponins measurements in acute cardiac care. Eur Heart J 2010, 31:2197-2206.
12. Hessel M, Michielsen E, Atsma D, Schalij M, van der Valk E, Bax W, Hermens W, van Dieijen-Visser MP, van der Laarse A: Release kinetics of intact and degraded troponin I and T after irreversible cell damage. Exp Mol Pathol 2008, 85:90-95.
13. Fishbein M, Wang T, Matijasevic M, Hong L, Apple F: Myocardial tissue troponins T and I. An immunohistochemical study in experimental models of myocardial ischemia. Cardiovasc Pathol 2003, 12:65-71.
14. Regwan S, Hulten E, Martinho S, Slim J, Villines T, Mitchell J, Ahmad S: Marathon running as a cause of troponin elevation: a systematic review and meta-analysis. J Interv Cardiol 2010, 23:443-450.
15. Zhu Y, Jenkins M, Brass D, Ravago P, Horne B, Dean S, Drayton N: Heterophilic antibody interference in an ultra-sensitive 3-site sandwich troponin I immunoassay. Clin Chim Acta 2008, 395:181-182.
16. Panteghini M: Assay-related issues in the measurement of cardiac troponins. Clin Chem Acta 2009, 402:88-93.
17. Panteghini M: Acute myocardial syndrome. Biochemical strategies in the troponin era. Chest 2002, 122:1428-1435.
18. European Heart Journal: Universal definition of myocardial infarction. Eur Heart J 2007, 28:2525-2538.
19. Wu A, Jaffe A: The clinical need for high-sensitivity troponin assays for acute coronary syndromes and the role of serial testing. Am Heart J 2008, 155:208-214.
20. Wu A, Lu Q, Todd J, Moecks J, Wians F: Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice. Clin Chem 2009, 55:52-58.
21. McRae A, Kavsak P, Lustig V, Bhargava R, Vandersluis R, Palomaki G, Yerna M, Jaffe A: Assessing the requirement for the 6 hour interval between specimans in the Americal Heat Association classification of myocardial infraction in epidemiology and clinical research. Clin Chem 2006, 52:816-818.
22. Reiter M, Twerenbold R, Reichlin T, Haaf P, Peter P, Meissner J, Hochholzer W, Stelzig C, Freese M, Heinisch C, Breidthardt T, Freidank H, Winkler K, Campodarve I, Gea J, Mueller C: Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. Eur Heart J 2011, 32:1379-1389.
23. Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S, Warnholtz A, Fröhlich M, Sinning S, Eleftheriadis M, Wild P, Schnabel R, Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner K, Münzel T, Blankenberg S: Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009, 361:868-877.
24. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C: Early diagnosis of myocardial infraction with sensitive cardiac troponin assays. N Engl J Med 2009, 361:858-867.
25. Apple F, Pearce L, Smith S, Kaczmarek J, Murakami M: Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of acute myocardial infarction and prediction of risk of adverse events. Clin Chem 2009, 55(5):930-937.
26. Giannitsis E, Becker M, Kurz K, Hess G, Zdunek D, Katus H: High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem 2010, 56(4):642-650.
27. Ottani F, Galvani M, Nicolini F, Ferrini D, Pozzati A, Di Pasquale G, Jaffe A: Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000, 140:917-927.
28. Heidenreich P, Alloggiamento T, Melsop K, McDonald K, Go A, Hlatky M: The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001, 38:478-485.
29. Khan N, Hemmelgam B, Tonelli M, Thompson C, Levin A: Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease a meta-analysis. Circulation 2005, 112:3088-3096.
30. Lim W, Qushmaq I, Devereaux P, Heels-Ansdell D, Lauzier F, Ismaila A, Crother M: Elevated cardiac troponin measurement in critically ill patients. Arch Int Med 2006, 166:2446-2454.
31. Roe C, Limbird L, Wagner G, Nerenberg S: Combined isoenzyme analysis in the diagnosis of myocardial injury: application of electrophoretic methods for the detection and quantitation of the creatine phosphokinase MB isoenzyme. J Lab Clin Med 1972, 80:577-590.
32. Sobel B, Shell W: Serum enzyme determination in the diagnosis and assessment of myocardial infarction. Circulation 1972, 45:71-482.
33. Lin J, Apple F, Murakami M, Luepker R: Rates of positive cardiac troponin I and creatine kinase MB mass among patients hospitalized for suspected acute coronary syndromes. Clin Chem 2004, 50:333-338.
34. Wolf P: Abnormalities in serum enzymes in skeletal muscle diseases. Am J Clin Pathol 1991, 95:293-196.
35. Mad P, Domanovits H, Fazelnia C: Human heart-type fatty acid binding protein as a point of care test in the early diagnosis of acute myocardial infarction. QJM 2007, 100:203-210.
36. O'Donoghue M, de Lemos J, Morrow D: Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006, 114:550-557.
37. Tanaka T, Sohmiya K, Kitaura Y, Takeshita H, Morita H: Clinical evaluation of point of care testing of heart-type fatty acid binding protein (H-FABP) for the diagnosis of acute myocardail infarction. J Immunoassay Immunochem 2006, 27:225-238.
38. Toop T, Donald J: Comparative aspects of natriuretic peptides physiology in nonmammalian vertebrates: a review. J Comp Physiol 2007, 174:189-204.
39. Piechota M, Banach M, Jacon A, Rysz J: Natriuretic peptides in cardiovascular diseases. Cell Molec Biol Lett 2008, 13:155-181.
40. Vanderhayden M, Goethals M, Verstreken S, De Bruyne B, Muller K, van Schuerbeeck E, Bartunek J: Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. JACC 2004, 2349-2354.
41. Vanderheyden M, Vrints C, Verstreken S, Bartunek J, Beunk J, Goethals M: B-type natriuretic peptide as a marker of heart failure: new insights from biochemistry and clinical applications. Biomarkers Med 2010, 42:315.
42. Maisel A, Mccord J, Nowak R, Hollander J, Wu A: Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003, 41:2010-2017.
43. Maisel A, Krishnaswarmy P, Nowak R, McCord J, Hollander J, Duc P, Omland T, Storrow A, Abraham W, Wu A, Clopton P, Steg P, Westheim A, Knudsen C, Perez A, Kazanegra R, Hermann H, McCullough PN: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
44. Coquet I, Darmon M, Doise J, Degres M, Blettery B, Schlemmer B, Gambert P, Quenot J: Performance of N-terminal-pro-B-type natriuretic peptide in critically ill patients:a prospective observational cohort study. Crit Care 2008, 12:R137.
45. Januzzi JJ, Camargo C, Anwaruddin S, Baggish A, Chen A, Krauser D, Tung R, Cameron R, Nagurney J, Chae C, Lloyd-Jones D, Brown D, Foran-Melanson S, Sluss P, Lee-Lewandrowski E, Lewandrowski K: The N-terminal ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) study. Am J Cardiol 2005, 95:948-954.
46. Jaffe A, Babuin L, Apples F: Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006, 48:1-11.
47. Oremus M, Raina P, Santaguida P, Balion C, McQueen M: A systematic review of BNP as a predictor of prognosis in persons with coronary artery disease. Clin Biochem 2008, 41:260-265.
48. Forfia P, Watkins S, Rame J, Stewart K, Shapiro P: Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. JACC 2005, 45:1667-1671.
49. Omland TC: Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart heart failure. Crit Care Med 2008, 36(Suppl):S17-S27.
50. Mclean A, Tang B, Nalos M, Huang S, Stewart D: Increased B-type natriuretic peptide is a strong predictor for cardiac dysfunction in intensive care patients. An Int Care 2003, 31:21-27.
51. Abroug F, Ouanes-Besbes L, Nciri N, Sellami N, Addad F, Hamda K: Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006, 174:990.
52. Kampaliotis D, Kirtane A, Ruisi C, Polonsky T, Malhotra A, Talmor D: Diagnostic and prognostic utility of brain natriuretic peptide in subjects admitted to ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest 2007, 131:964-971.
53. Mclean A, Huang S, Nalos M, Tang B, Stewart D: The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptides: concentrations in the critically ill. Crit Care Med 2003, 31:2611-2618.
54. McLean A, Huang S, Hyams S, Poh G, Nalos M, Pandit R, Balik M, Tang B, Seppelt I: Prognostic values of B-type natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007, 35(4):1019-1026.
55. Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettilä V: FINNSEPSIS Study Group: predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007, 35:5.
56. Phua J, Koay E, Lee K: Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock. Shock 2008, 29(3):328-333.
57. Kandil E, Burack J, Sawas A, Bibawy H, Schwartzman A, Zenilman M, Bluth M: B-type natriuretic peptide: a biomarker for the diagnosis and risk stratification of patients with septic shock. Arch Surg 2008, 143(3):242-246.
58. Cuthbertson B, Patel R, Croal B, Barclay J, Hillis G: B-type natriuretic peptide and the prediction of outcomein patients admitted to intensive care. Anaesthesia 2005, 60:16-21.
59. Christenson R: What is the value of B-type natriuretic peptide peptide testing for diagnosis, prognosis, or monitoring of the critically ill adult patients in intensive care? Clin Chem Lad Med 2008, 46(11):1524-1532.
60. Nishikimi T, Asakawa H, Iida H, Matsushita Y, Shibasaki I: Different secretion patterns of two molecular forms of cardiac adrenomedullin in pressure-and volume-overloaded human heart failure. J Card Fail 2004, 10:321-327.
61. Miyao Y, Nishikimi T, Goto Y, Miyazaki S, Daikoku S: Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. Heart 1998, 79:39-44.
62. Kucher N, Goldhaber S: Cardiac biomarkers for risk stratification of patients with acute pulmonary embolus. Circulation 2003, 108:2191-2194.
63. La Vecchia L, Ottani F, Favero L, Spadaro G, Rubboli A, Boanno C: Increased cardiac troponin I on admission predicts inhospital mortality in acute pulmonary embolism. Heart 2004, 90:633-637.
64. Vuilleumier N, Le Gal G, Cornily C, Hochstrasser D, Bounameaux H, Aujesky D, Righini M: Is N-terminal pro-brain natriureticpeptide superior to clinical scores for stratification in nonmassive pulmonary embolus? J Thromb Haemost 2010, 8:1433-1435.
65. European Heart Journal: Guidelines on the diagnosis and management of acute pulmonary embolism The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008, 29:2276-2315.
66. Lankeit M, Konstantinides S: Mortality risk assessment and the role of thrombolysis in pulmonary embolus. Clin Chest Med 2010, 31:759-769.
67. Puls M, Dellas C, Lankeit M: Elevated heart-type fatty acid binding protein levels on admission predicts an adverse outcome in normotensive patients with acute pulmonary embolus. Eur Heart J 2007, 28:224-229.
68. Boscheri A, Wunderlich C, Langer M, Schoen S, Wiedermann B, Stolte D, Elmer G, Barthel P, Strasser R: Correlation of heart-type fatty acid-binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk. Am Heart J 2010, 160:294-300.
69. Turner A, Tsamitros M, Bellomo R: Myocardial cell injury in septic shock. Crit Care Med 1999, 27:1775-1780.
70. Agewall S, Giannitsis E, Jernberg T, Ka H: Troponin elevation in coronary vs. non-coronary disease. Eur Heart J 2011, 32:404-411.
71. Bouhemad B, Nicolas-Robin A, Arbelot C, Arthaud M, Feger F, Rouby JJ: Isolated and reversible impairment of ventricular relaxation in patients with septic shock. Crit Care Med 2008, 36(3):766-774.
72. ver Elst K, Spapen H, Nguyen D, Garbar C, Huyghens L, Gorus F: Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem 2000, 46(5):650-657.
73. Rosjo H, Varpula M, Hagve T, Karlsson S, Ruokonen E, Pettila V, Omland T: Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcomes. Intensive Care Med 2011, 37:77-85.
74. Post F, Weilemann L, Messow C, Sinning C, Munze LT: B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients. Crit Care Med 2008, 36:3030-3037.
75. Nellessen U, Goder S, Schobre R, Abawi M, Hecker H, et al: Serial analysis of troponin I levels in patients with ischemic and nonischemic dilated cardiomyopathy. Clin Cardiol 2006, 29:219-224.
76. Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A: Prevalence and determinants of troponin T elevation in the general population. Circulation 2006, 113(16):1958-1965.
77. Liu Z, Cui L, Wang Y, Guo Y: Cardiac troponin I and ventricular arrhythmia in patients with chronic heart failure. Eur J Clin Invest 2006, 36:466-472.
78. Latini R, Masson S, Anand IS, Missov E, Carlson M: Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 116:1242-1249.
79. Masson S, Latini R, Anand I: An update on cardiac troponins as circulating biomarkers in heart failure. Curr Heart Fail Rep 2010, 7:15-21.
80. Wu A, Jaffe A, Apple F, Jesse R, Francis G, Morrow D, Newby L, Ravkilde J, Tang W, Christenson R, NACB Committee, Cannon C, Storrow A: National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or Nterminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 2007, 53:2086-2096.
81. Jacobs L, van de Kerkhof J, Mingels A, Kleijnen V, van der Sande F, Wodzig W, Kooman J, van Dieijen-Visser M: Haemodialysis patients longitudinally assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and cardiac troponin I assays. Ann Clin Biochem 2009, 46:283-290.
82. Hickman P, McGill D, Talaulikar G, Hiremagalur B, Bromley J, Rahman A, Koerbin G, Southcott E, Potter J: Prognostic efficacy of cardiac biomarkers for mortality in dialysis patients. Int Med 2009, 39:812-818.
83. Rana R, Vlahakis N, Daniels: B-type Natriuretic peptide in the assessment of acute lung injury and cardiogenic pulmonary edema. Crit Care Med 2006, 34:1941-1946.
84. Mueller C, Maisel A, Mebazza A, Fillippatos G: The use of b-type natriuretic peptides in the intensive care unit. Congest Heart Failure 2008, 14(4 suppl 1):43-45.
85. Zapata L, Vera P, Roglan A, Gich I, Ordonez-Llanos J, Betbese A: B-type natriuretic peptide for prediction and diagnosis of weaning failure from cardiac origin. Intensive Care Med 2011, 37:477-485.
86. Mekontso-Dessap A, de Prost N, Girou E, Braconnier F, Lemaire F, Brun-Buisson C, Brochard L: B-type natriuretic peptide and weaning from mechanical ventilation. Intensive Care Med 2006, 32(10):1529-1536.
87. Sinha M, Roy D, Gaze D, Collinson P, Kaski J: Role of 'ischaemia modified albumin,' a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med 2004, 29:29-34.
88. Apple F, Smith S, Pearce L, Murakami M: Assessment of the multiple-biomarker approach for diagnosis of myocardial infarction in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2009, 55:93-100.
89. Slater M: The use of multi-cardaic biomarker panel in the intensive care unit: a prospective study [Med Hon Thesis] Sydney University Medical School; 2009.
90. Núñez J, Sanchis J, Bodí V, Fonarow G, Núñez E, Bertomeu-González V, Miñana G, Consuegra L, José Bosch M, Carratalá A, Chorro F, Llàcer A: Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J 2010, 31:1752-1763.
91. Small E, Frost R, Olson E: MicroRNAs add a new dimension to cardiovascular disease. Circulation 2010, 121:1022-1032.
92. Fichtlscherer S, Rosa S, Fox H: Circulating MicroRNAs in patients with coronary artery disease. Circ Res 2010, 107:677-684.
93. Contu R, Latronico M, Condorelli G: Circulating MicroRNAs as potential biomarkers of coronary artery disease-a promise to be fulfilled? Circ Res 2010, 107:573-574.
94. Bartel D: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
95. Wang G-K, Zhu J, Zhang J-T, Li Q, Li Y, He J, Qin Y, Jing Q: Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010, 31:659-666.
96. Alessandra Y, Devanna P, Limana F, Straino S: Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010, 31:2765-2773.
97. Condorelli G, Latronico M, Dorn G: MicroRNAs in heart disease: putative novel therapeutic targets? Eur Heart J 2010, 31:649-658.